196 related articles for article (PubMed ID: 37234980)
1. Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models.
Awasthi N; Schwarz MA; Kaurich Q; Zhang C; Hilberg F; Schwarz RE
Front Oncol; 2023; 13():1145999. PubMed ID: 37234980
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.
Awasthi N; Schwarz MA; Zhang C; Klinz SG; Meyer-Losic F; Beaufils B; Thiagalingam A; Schwarz RE
Mol Cancer Ther; 2022 Jul; 21(7):1149-1159. PubMed ID: 35500018
[TBL] [Abstract][Full Text] [Related]
4. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
[TBL] [Abstract][Full Text] [Related]
5. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
7. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Suzuki N; Nakagawa F; Matsuoka K; Takechi T
Oncol Rep; 2016 Dec; 36(6):3123-3130. PubMed ID: 27805254
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
Reck M; Mellemgaard A
Biologics; 2015; 9():47-56. PubMed ID: 26170616
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma.
Patwardhan PP; Musi E; Schwartz GK
Mol Cancer Ther; 2018 Nov; 17(11):2329-2340. PubMed ID: 30166401
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Awasthi N; Hinz S; Brekken RA; Schwarz MA; Schwarz RE
Cancer Lett; 2015 Mar; 358(1):59-66. PubMed ID: 25527450
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Grohé C; Wehler T; Dechow T; Henschke S; Schuette W; Dittrich I; Hammerschmidt S; Müller-Huesmann H; Schumann C; Krüger S; Atz J; Kaiser R
Transl Lung Cancer Res; 2022 Oct; 11(10):2010-2021. PubMed ID: 36386456
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
18. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]